OFFICE OF FISCAL ANALYSIS
Legislative Office Building, Room 5200
Hartford, CT 06106 (860) 240-0200
http://www.cga.ct.gov/ofa
sSB-262
AN ACT REQUIRING MANUFACTURERS OF BRAND NAME
PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS
TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS.
Primary Analyst: ME 3/3/21
Contributing Analyst(s): ME
Reviewer: PR
OFA Fiscal Note
State Impact:
Agency Affected Fund-Effect FY 22 $ FY 23 $
Consumer Protection, Dept. GF - Potential
Cost
80,071 80,071
State Comptroller - Fringe
Benefits
1
GF - Potential
Cost
32,202 32,202
Note: GF=General Fund
Municipal Impact: None
Explanation
The bill results in a potential total cost to the state of $112,273 in FY
22 and FY 23 for one attorney, to the extent the new Connecticut Unfair
Trade Practice violation, pursuant to the bill, results in numerous new
investigations.
The Out Years
The annualized ongoing fiscal impact identified above would
continue into the future subject to inflation.
1
The fringe benefit costs for most state employees are budgeted centrally in accounts
administered by the Comptroller. The estimated active employee fringe benefit cost
associated with most personnel changes is 41.3% of payroll in FY 22 and FY 23.